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increases apolipoprotein-E, provides no cognitive
benefit in mutant APP/PS1 mice
Katherine D LaClair1,4†, Kebreten F Manaye5†, Dexter L Lee5, Joanne S Allard5, Alena V Savonenko1,3,
Juan C Troncoso1,3* and Philip C Wong1,2,4*Background: Though the precise cause(s) of Alzheimer’s disease (AD) remain unknown, there is strong evidence
that decreased clearance of β-amyloid (Aβ) from the brain can contribute to the disease. Therapeutic strategies to
promote natural Aβ clearance mechanisms, such as the protein apolipoprotein-E (APOE), hold promise for the
treatment of AD. The amount of APOE in the brain is regulated by nuclear receptors including retinoid X receptors
(RXRs). Drugs that activate RXRs, including bexarotene, can increase APOE and ABCA1 production, and have been
shown to decrease the Aβ burden and improve cognition in mouse models of Aβ amyloidosis. Although recent
bexarotene studies failed to replicate the rapid clearance of Aβ from brains, behavioral and cognitive effects of this
compound remain controversial.
Findings: In efforts to clarify these behavioral findings, mutant APP/PS1 mice were acutely dosed with bexarotene.
While ABCA1 was upregulated in mutant APP/PS1 mice treated with bexarotene, this drug failed to attenuate Aβ
plaques or cognitive deficits in these mice.
Conclusions: We recommend rigorous preclinical study to evaluate the mechanism and utility of such a
compound for AD therapy.
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The principle pathological characteristics of Alzheimer’s
disease (AD) include the extracellular deposition of β-
amyloid (Aβ) plaques and intracellular aggregation of
tau in the brain, abnormal synaptic function, and
chronic inflammatory responses in neural tissue. A well-
studied mouse model of Aβ amyloidosis is the double
transgenic APPswe/PS1ΔE9 mouse that exhibits Aβ
plaques in the hippocampus and cortex beginning at 6
months of age [1]. The progression of Aβ deposition oc-
curs more rapidly in these transgenic females than in
males [2]. While Aβ has a clear link to AD – either dir-
ectly or through the processing mechanisms of its pre-
cursor protein APP – Aβ is also present in healthy* Correspondence: troncoso@jhmi.edu; wong@jhmi.edu
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reproduction in any medium, provided the orindividuals in the form of low molecular weight soluble
Aβ peptides that likely serve physiological roles [3].
Levels of Aβ peptides are managed by clearance mecha-
nisms in the brain that activate microglia to facilitate the
removal of Aβ from the extracellular space [4]. The most
prominent of these clearance components is the choles-
terol transporter apolipoprotein-E (ApoE) because the
E4 allele as compared to that of E2 or E3 is the most sig-
nificant risk factor for the development of non-familial
(sporadic) AD. Individuals with APOE4 have a pro-
nounced increase in Aβ oligomerization [5] and AD in-
cidence [6,7] relative to carriers of the other APOE
alleles. APOE4 has also been found to have decreased af-
finity for Aβ compared to APOE3 or APOE2, but only
when activated by lipidation [8], which implies that dys-
function in the regulation and action of APOE isoforms
can play contributing roles in the pathogenesis of AD.
The convergence of this data indicates that promoting
APOE may be a productive therapeutic strategy in AD.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
LaClair et al. Molecular Neurodegeneration 2013, 8:18 Page 2 of 10
http://www.molecularneurodegeneration.com/content/8/1/18The transcription of APOE is facilitated by activation
and heterodimerization of the nuclear receptor retinoid X
receptor (RXR) with its partner receptors peroxisome acti-
vated receptors (PPARγ) or liver X receptors (LXR). These
nuclear receptors also activate lipidators such as ABCA1
[9,10], which appear necessary for the Aβ clearing abilities
of ApoE [8,11,12]. Therefore, a number of RXR agonists
have been tested as a potential therapeutic mechanism of
increasing Aβ clearance through ApoE. Bexarotene is one
such agonist, which is selective for RXR and is FDA-
approved for the treatment of cutaneous T-cell lymphoma.
Cramer et al. [13] conducted studies with bexarotene in
transgenic mouse models of Aβ amyloidosis. They re-
ported that acute treatment with bexarotene upregulated
ABCA1 and ApoE, rapidly reduced the Aβ plaque burden
in the brain, and ameliorated cognitive deficits in these
models. However, several groups have failed to replicate
the effect of bexarotene on Aβ plaque burden in these
and other related mouse models, despite achieving
upregulation of the proposed targets ApoE and ABCA1
[14-17]. While the original experiments were conducted
on mouse models (Tg2576 and APPswe/PS1ΔE9) that ex-
hibit significant gender-related pathological differences
(18 and 2, respectively), no distinction of gender was made
in their analysis [13]. In using a small cohort of mice in
the studies, these gender differences could skew treatment
groups leading to a false positive treatment effect. More-
over, gender-related differences are important in the
evaluation of any RXR agonist or other compounds influ-
encing this pathway because ApoE function can be modi-
fied by gender [19,20].
In this study, we attempted to clarify this gender dis-
crepancy by measuring brain Aβ plaque load in male
and female cohorts of APPswe/PS1ΔE9 mice acutely dosed
with bexarotene. We used two different formulations of
bexarotene, one in DMSO (as used by Cramer et al.
[13]) and one in corn oil to assess any potential issues
with DMSO toxicity. Since RXR and LXR agonists have
been shown to modulate microglial activity to dampen
their inflammatory responses and enhance their clear-
ance abilities [21], we also examined microglial activa-
tion in these treated mice. Finally, no study has yet
replicated the effect of bexarotene on fear memory, and
its cognitive effects remain controversial. Therefore, we
evaluated the effect of bexarotene on context-dependent
and conditioned-stimulus-dependent fear memory.
Results
To confirm the apparent benefit of acute treatment with
bexarotene [13], we initially dosed two cohorts of 8
month old female APPswe/PS1ΔE9 mice with 100 mg/kg
of this RXR agonist (or indicated vehicle) by daily oral
gavage. We analyzed the effects of treatment on ABCA1
levels in APPswe/PS1ΔE9 mice, and found that the use ofDMSO or corn oil as a vehicle does not create a signifi-
cant difference in the relative means of bexarotene
treated groups normalized to their respective vehicle
[(M=1.570, SD=0.203) and (M=1.641, SD=0.157), re-
spectively F(1,10)=0.044, p=0.837], and that there was no
interaction between vehicle used and treatment group.
As expected, we found that bexarotene significantly
increased levels of ABCA1 by 50% after three days
of treatment (Figure 1A) [* F(1,13)=5.261, p=0.027],
confirming that this compound engaged the expected
targets in the brains of these mice. To assess the impact
of bexarotene on amyloid burden in male and female
mice, we dosed an 8 month (DMSO vehicle) and an 11
month old (corn oil vehicle) cohort of APPswe/PS1ΔE9
mice. Again, we found no significant effect of vehicle
type on Aβ levels [cortex F(1,29)=0.277, p=0.965, hippo-
campus F(1,29)=3.266, p=0.081], and no interaction be-
tween vehicle used and treatment group. In contrast to
findings of Cramer et al. [13], no significant differences
in Aβ plaque burden were observed in brains of
bexarotene treated APPswe/PS1ΔE9 mice compared to ve-
hicle [cortex F(1,29)=0.002, p=0.965, hippocampus F
(1,29)=0.398, p=0.533] (Figure 1B). Though the sample
sizes for each group are small, sample size estimates
for each experiment showed that they each have a
power ≥88%. In addition, the inability of bexarotene to
alter plaque levels in this model has recently been reported
by additional groups [14-17]. While there has been in-
creasing evidence that plaques may not be as informative
correlates of disease as soluble forms of Aβ, the inability
of bexarotene to alter soluble Aβ levels in this mouse
model has also been recently reported [14-17]. Notably,
we observed a significant main effect of gender on
plaque levels in 11 month old mice. Male groups had
significantly lower plaque load compared to female
groups [* cortex, F(1,19)=20.177, p<0.0005 and ** hippo-
campus F(1,19)=14.045, p=0.001] (Figure 1C). In 8 month
old mice, males were tested, so that age group could
not be included in the analysis for a gender effect, but
gender differences in plaque load have been reported as
early as six months of age in this mouse model [18].
Analysis of microglial immunoreactivity using an anti-
sera specific to ionized calcium binding adaptor molecule
1 (Iba1), a microglial inflammatory and phagocytic marker
[22], revealed a similar pattern between APPswe/PS1ΔE9
mice treated with bexarotene or vehicle (Figure 2). Despite
the potential of RXR agonists to modulate the microglial
activation present in APPswe/PS1ΔE9 mice, no significant
effect of bexarotene was observed compared with vehicle
administration [cortex F(1,27)=2.231, p=0.147, and hippo-
campus F(1,27)=2.127, p=0.156] (Figure 2A). No signifi-
cant main effect of gender was found, and no interaction
was detected between gender and treatment. Microglial
morphology was also analyzed, as described in [23].
Figure 1 Bexarotene significantly increases ABCA1 in the brains of APPswe/PS1ΔE9 mice, but does not alter Aβ plaques. (A) Representative
Western blot (Vehicle (−), Bexarotene (+)) of ABCA1 in cortex of 8.5 mo. female mice, and graph of quantification normalized to β-tubulin-III.
Bexarotene significantly increases ABCA1 expression by 50% after three days of gavage treatment [* F(1,13)=5.261, p=0.027]. (B) Percent brain area
covered by plaques in 8 month (ubiquitin) and 11 month (7B6) female mice, calculated by stereological estimation on sections stained with the
antibodies indicated. No significant differences in plaque burden were detected between treatment groups. N-values: Ubiquitin – veh=4, bex=6;
7B6 – veh=3, bex=5. Error bars represent standard deviation. (C) Gender comparison between % plaque area in 11 mo. mice, calculated by
stereological estimation on sections stained with 7B6 antibody. Males had significantly lower plaque load compared to females in both treatment
groups [* cortex, F(1,19)=20.177, p<0.0005 and ** hippocampus F(1,19)=14.045, p=0.001]. Error bars represent standard deviation. N-values:
females- veh=3, bex5; males- veh=7, bex=8. Sample size estimates show this experiment has power of 88%. Representative images of plaques in
APPswe/PS1ΔE9 mice, stained with 7B6 - (D) M Veh (E) M Bex (F) F Veh (G) F Bex - and ubiquitin - (H) F Veh (I) F Bex.
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(Figure 2D) animals show a transitional amoeboid (activa-
ting) morphology with clustering of these activatedmicroglia, which was unchanged after administration of
bexarotene (Figure 2C and E, respectively). In contrast,
microglia from female and male non-transgenic animals
Figure 2 Immunoreactivity of glia is unchanged in APPswe/PS1ΔE9 mice following administration of bexarotene. (A) IBA1 levels in 11
month old male and female APPswe/PS1ΔE9 mice are unaffected by bexarotene treatment in both cortex [F(1,27)=2.231, p=0.147] and
hippocampus [F(1,27)=2.127, p=0.156], and no significant effect of gender was detected [F(1,27)=0.665, p=0.422]. No significant interactions were
detected. Error bars represent standard deviation. N-values: non-transgenics (veh), males=5, females=5; APPswe/PS1ΔE9, males: Bex =8, Veh=7,
females: Bex=5, Veh=3. Representative images of IBA1 staining and microglial morphology in (B) F tg Veh, (C) F tg Bex, (D) M Tg Veh and (E) M
Tg Bex. Scale bars = 500 um large images and 50 um on inserts. Morphology shows an amoeboid (active) state with clusters of activated
microglia in APPswe/PS1ΔE9 animals (B,D). This morphology and clustering appears unchanged by treatment with bexarotene (C,E).
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in Additional File 1. A recent study analyzing the presence
of Aβ in Iba1-positive microglia also failed to show an ef-
fect of bexarotene on Aβ uptake and clearance [17].
Finally, we analyzed the effects of bexarotene treat-
ment on context-dependent freezing behavior in 8
month old female APPswe/PS1ΔE9 and littermate non-
transgenic mice according to the protocol described by
Cramer et al. [13]. Behavioral measures in males and fe-
males were assessed separately due to gender differences
present in this mouse model [18]. In the training session,
APPswe/PS1ΔE9 mice receiving vehicle and bexarotenetreatment demonstrated similar levels of context-
dependent freezing [F(7,44)=3.905, p=0.002, Tukey: male
nontg p=1.000, male tg p=0.182, female nontg p=0.999,
female tg p=1.000] (see Figure 3A) indicating that acqui-
sition of fear response was not significantly affected by
genotype, sex, or treatment.
Testing for context-dependent fear memory yielded
no significant differences among any of the groups
[F(7,44)=1.794, p=0.113]. This finding was not surprising
given the strong unconditioned stimulus and its multiple
presentations in the protocol described in [13], which
was used here for replication purposes. Of particular
Figure 3 Bexarotene fails to produce an effect on context-dependent or CS-dependent freezing behavior in APPswe/PS1ΔE9 mice.
Percent of time spent freezing was measured to quantify long term fear memory. (A) In the training session, APPswe/PS1ΔE9 mice receiving
bexarotene treatment demonstrated similar levels of context-dependent freezing compared to their vehicle-treated counterparts [F(7,44)=3.905,
p=0.002; Tukey: male nontg p=1.000, male tg p=0.182, female nontg p=0.999, female tg p=1.000]. In the context-dependent testing session, no
significant differences were detected among any of the groups [F(7,44)=1.794, p=0.113]. (B) Analysis of CS-dependent fear responses show no
significant effect of bexarotene on freezing behavior in APPswe/PS1ΔE9 male or female mice. A significant gender difference was detected between
males and females in both non-transgenic and APPswe/PS1ΔE9 animals treated with vehicle [main effect of gender F(1,15)=23.506, p<0.0005; main
effect of genotype F(1,15)=1.898, p=0.189, no significant interaction; females [M=42.006,SD=17.65] show lower levels of freezing than males
[M=76.260,SD=10.50]. These gender-related differences were not observed in mice treated with bexarotene [males M=48.79, SD=20.71; females
M=54.55, SD=21.48; main effect of sex F(1,27)=0.630, p=0.434; main effect of genotype F(1,27)=1.388,p=0.249; no significant interaction]. The
condition of equality of variances was not met for this test. For all parts, error bars represent standard deviation. N-values females: nontg-veh=4,
AP-veh=7, nontg-bex=8, AP-bex=13. N-values males: nontg-veh=4, AP-veh=4, nontg-bex=6, AP-bex=5.
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behavior in Figure 3A were almost double those
reported in Cramer et al. [13] using these testing param-
eters. We also performed a high-sensitivity alternative
conditioning paradigm, consisting of a short pre-
exposure period and a single delivery of the uncondi-
tioned stimulus as described in [24] and the Methods.Using this paradigm we detected a significant freezing
deficit in 8 month old APPswe/PS1ΔE9 females compared
to non-transgenic littermates [F(1,17)=5.943, p=0.026]
(Figure 4). However, this deficit was not persistent at 10
months of age [F(1,18)=2.824, p=0.110] with an oppos-
ing trend of increased freezing in APPswe/PS1ΔE9 females
(Figure 4). These data indicate that freezing behavior
Figure 4 Context-dependent freezing in APPswe/PS1ΔE9 female mice and non-transgenic littermates following a high-sensitivity
conditioning protocol. A deficit is not yet present in APPswe/PS1ΔE9 females at 5 months of age [F(1,17)=0.684, p=0.420]. Context-dependent
freezing deficits are detectable in APPswe/PS1ΔE9 females at 8 months of age [*F(1,17)=5.943, p=0.026], but do not persist to 10 months of age
[F(1,18)=2.824, p=0.110]. N-values: 5 month- nontg=9, APP/PS1=10, 8 month- nontg=8, APP/PS1=11, 10 month- nontg=12, APP/PS1=8. Error bars
represent standard deviation.
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icits in this mouse model.
We also analyzed conditioned stimulus (CS)-dependent
fear responses, and found no effect of bexarotene on
freezing behavior in APPswe/PS1ΔE9 mice compared to
non-transgenic littermates (Figure 3B). However, we again
observed an unexplained trend of freezing deficit in non-
transgenic males treated with bexarotene as compared to
vehicle- and bexarotene-treated APPswe/PS1ΔE9 males
(Figure 3B). In addition, a significant gender difference
was also detected in this task between males and females
of vehicle-treated non-transgenic and APPswe/PS1ΔE9 ani-
mals [main effect of gender F(1,15)=23.506, p<0.0005;
main effect of genotype F(1,15)=1.898, p=0.189, no signifi-
cant interaction] with females [M=42.006,SD=17.65]
showing lower levels of freezing than males [M=76.260,
SD=10.50] (Figure 3B). These gender-related differences
were no longer observed in mice treated with bexarotene
[males M=48.79, SD=20.71, females M=54.55, SD=21.48;
main effect of sex F(1,27)=0.630, p=0.434; main effect of
genotype F(1,27)=1.388,p=0.249; no significant interaction.
The condition of equality of variances was not met for
this test].
Discussion
Our data failed to replicate the apparent benefit of acute
bexarotene treatment in mouse models of Aβ amyloid-
osis previously reported [13]. It is unknown whether
chronic administration of bexarotene or alternate dosing
strategies would have a beneficial effect. Nevertheless,our failure to replicate the initial observations empha-
sizes the importance of gender-related differences in the
APPswe/PS1ΔE9 mouse model, and other work indicates
that these differences may extend to humans [19,20].
Since the completion of this study, bexarotene has been
tested in other animal models of Aβ amyloidosis, includ-
ing APP/PS1-21 [17], 5XFAD [17], and APPswe/PS1ΔE9
with APOE3/4 allele knock-in [14], as summarized in
Table 1. All have failed to replicate a change in soluble
or plaque forms of Aβ, with the exception of the non-
pathogenic soluble Aβ40 species, which decreased after
acute treatment with bexarotene in the 5XFAD mouse
model, but not in the APPswe/PS1ΔE9 or the APP/PS1-21
models [17].
Importantly, we are unable to replicate a robust and
persistent fear conditioning deficit in the APPswe/PS1ΔE9
mouse model, even with an alternate, highly sensitive
testing paradigm [24]. Fear conditioning is the sole be-
havioral measure previously used to test bexarotene in
this model [13]. In APPswe/PS1ΔE9 mice with APOE3/4
knock-in, bexarotene was reported to rescue deficits in
the Radial Arm Water Maze at 7 months of age [14],
but this testing was also performed on mixed gender
cohorts of n=5 per group, introducing a potential false-
positive treatment effect. Therefore, the current cogni-
tive preclinical data do not validate the potential of this
drug for Alzheimer’s therapy.
Together, the array of published work on the effect of
bexarotene on pathology and cognitive impairment in
mouse models of Aβ amyloidosis produces no rigorous
Table 1 Summary of recently published findings on bexarotene in mouse models of Aβ amyloidosis related to the
study presented here (first row)
Model Age (months) Days of treatment Brain insoluble/plaque Aβ Brain soluble Aβ Fear conditioning
APP swe/PS1 ΔE9 8 and 11 3, 7 and 14, No effect N/A No effect
APP/PS1 + APOE3/4 [14] 7 15 No effect No effect N/A
APP swe/PS1ΔE9 [15] 7 11 No effect No effect N/A
APP swe/PS1ΔE9 [16] 10 14 No effect No effect N/A
APPswe/PS1ΔE9 [17] 6 7 No effect No effect N/A
5XFAD[17] 3-4 7 No effect Decrease Aβ40 only N/A
APP/PS1-21[17] 9 26 No effect No effect N/A
N/A indicates that the listed data point was not reported. Superscript numbers indicate reference number of the original work.
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treatment of Alzheimer’s disease (Table 1). There are po-
tential discrepancies in the formulation of bexarotene
used in replicating studies as compared to the original
experiments [13,16] due to lack of availability of this for-
mulation to other research groups. While the consistent
upregulation of ABCA1 and ApoE using various formu-
lations of bexarotene [13-17] indicates that it does in-
deed activate the proposed targets, these may not be the
true mechanism of action responsible for the changes
observed in Cramer et al. [13]. In light of our and other
groups [14-17] overall failures to replicate the key find-
ings on bexarotene in mouse models of Aβ amyloidosis,
we recommend that the original formulation be made
available for rigorous preclinical studies in multiple
mouse models in order to clarify the existing discrepan-





jax) were used. 8 month and 11 month old APPswe/
PS1ΔE9 mice were housed on a 14 hr dark:10 hr light
cycle in standard cages with 2–5 mice each and given
free access to food and water. Bexarotene (ChemieTek)
was dissolved in a vehicle of <15% DMSO in milk or in
corn oil, as indicated in the corresponding figure legends.
Mice were weighed at the beginning of the treatment
period and the necessary volume of solubilized bexarotene
was calculated to produce a concentration of 100 mg/kg
for each animal. Animals were gavaged with vehicle or
bexarotene solution daily for 3, 7, or 14 days, as indicated.
Studies were performed on mixed gender or females only,
where indicated.
Brain ABCA1 quantification
Mice were sacrificed two hours after the day three gav-
age using brief CO2 exposure, followed immediately by
decapitation. Brains were removed and one hemisphere
was collected for ABCA1 quantification. Cortices werequickly dissected on ice with cold forceps. Samples were
placed on dry ice in labeled, pre-cooled microfuge tubes.
Samples were frozen at −80°C until use. Fresh, cold
RIPA buffer (10× volume of sample) with Protease In-
hibitor Cocktail was added to samples on ice and tissue
was mechanically dissociated using 1mL pipet tips. Sam-
ples were sonicated with brief pulses on ice, and cen-
trifuged at 14000 rpm for 25 min at 4°C. Supernatants
were transferred to new labeled microfuge tubes and kept
on ice during protein estimation, or stored at −80°C until
use. Protein concentration was estimated using the BCA
Assay, and analyzed by the Epoch Com6 spectrophotom-
eter (BioTek) with Gen5 analysis software. Samples for
protein blot were prepared containing 1.0-1.5 μg protein/
μL of sample solution. Samples were mixed, heated at
70°C for five minutes, then cooled and a volume con-
taining 30 μg of protein was loaded into wells of 4-12%
Bis-Tris gels (Novex) with MOPS running buffer. Gel was
run for 120 min at 120 volts, then transferred to a PVDF
membrane for 150 min at 30v. Membranes were probed
with ABCA1 mouse monoclonal antibody and with anti-
sera against β-tubulin III as a loading control, and were in-
cubated with HRP-conjugated secondary antibodies and
exposed to HRP substrate. Exposed films were scanned
without any background- or noise-subtraction and ana-
lyzed using ImageJ software. The relative optical density of
each band was calculated using the area under the curve
of lane profile plots on unaltered images. The experiment
was replicated in triplicate, and the mean optical density
(OD) was calculated.
Aβ Plaque quantification
Mice were gavaged with 100 mg/kg bexarotene for 14
days and sacrificed as described above, and hemispheres
were immediately immersed in 4% paraformaldehyde for
24 hours at 4°C. Brains were then moved to PBS solu-
tion for 24 hours at 4°C, followed by another change of
PBS for storage until use. The tissue was then embedded
in paraffin and sectioned into 10 μm coronal slices (7B6-
stained) or 10 μm sagittal slices between 1.2 and 1.5 mm
from the midline (ubiquitin-stained). Sections were
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7B6 antibodies (Abcam) to detect Aβ plaques. Plaque area
was calculated using the Area Fraction Fractionator probe
in the Stereo Investigator stereology program. The coun-
ting frame was 150x150 with gridsizes 500x500 μm for
cortex and 300x300 μm for hippocampus, and a grid spa-
cing of 10 μm. Plaque area for hippocampus and cortex
were measured and normalized to the total area of the
brain region for each animal. Data was collected and veri-
fied by two independent investigators, blinded to groups.
Iba-1 Quantification and morphological analysis
Animals were sacrificed after 14 days of gavage and their
tissues perfused. The brain tissue of each of the animals
was removed and placed in a 30% sucrose preservative,
and sectioned to a thickness of 40 μm on a freezing
microtome. Every eighth section was immunostained
with anti-Iba1 antibody (1:1000, Wako, cat. #019-19741).
Morphology of resting (ramified) and active (amoeboid)
microglia was analyzed according to the guidelines spe-
cified in [23]. Briefly, ramified microglia are identified
with a small cell body and long, thin projections with
distal branching. In contrast, active microglia exhibit a
shortening of projections and enlargement of the cell
body as they are reabsorbed, leading to an amoeboid
morphology.
Fear conditioning
All mice used for these studies were generated by breed-
ing a single cohort of 10 male and 20 female mice from
the line described above. Animals were gavaged with ve-
hicle or bexarotene (100mg/kg) solution daily for 7 days.
Behavioral tests were performed in the morning before
the daily gavage to minimize any effect of stress from this
procedure on behavior. Three days before the start of the
test period, animals were handled and the tails marked
with permanent marker to eliminate stress caused by
checking ear-tags just prior to behavioral testing. The fol-
lowing two days before behavioral testing, each animal
was handled and separately habituated to empty waiting
cages in a separate room adjacent to the testing room for
ten minutes.
Protocol 1
Context- and Cue-dependent fear conditioning was
conducted as described in Cramer et al. [13], beginning
after 4 days of gavage (before the 5th administration).
Conditioning was performed in a test chamber with a
shock grid floor and a contextual striped and checkered
pattern on three of the walls. Testing and data collection
were automated by ANY-Maze 4.70 software (Stoelting
Co., Wood Dale, IL) according to the following protocol
parameters: Light in the chamber 1.5 visible + 1.5 Infra-
red, Fan ON (65 dB), smell 30% Ethanol, Freezing ONThreshold = 25 msec, Freezing OFF Threshold = 30
msec, Minimum Freezing Duration = 500 msec.
Training session
Mice were placed in empty waiting cages for ten minutes
prior to the start of the test, then placed in the test cham-
ber and allowed to explore for 120 seconds. Mice were
then exposed to a conditioned stimulus (CS, 83dB and
2800Hz) for 30 seconds, followed by a 2 second delay, and
finally the unconditioned stimulus (US, 0.6 mA) for two
seconds. Mice remained in the chamber for an additional
30 seconds to measure immediate freezing response fol-
lowing the CS/US pairing. This sequence was repeated
four times for each animal.
Context dependent freezing
Context-dependent fear behavior was analyzed 24 hours
later. Mice were placed in the same test chamber for five
minutes without any CS or US administration, and freez-
ing behavior was measured throughout the test.
Conditioned Stimulus (CS)-dependent freezing
An additional 24 hours later, mice were tested for CS-
dependent freezing behavior. Mice were placed in a novel
test chamber with plain white walls on all sides and a
solid floor. Bedding was placed in the bottom of this new
chamber, as well as a small paper towel with 1:100 dilu-
tion of vanilla extract (McCormick) in water. Mice were
allowed to explore the chamber for 120 seconds, followed
by CS presentation for 30 seconds, and a 30 second delay
to measure immediate freezing response. This sequence
was repeated four times for each animal.
Protocol 2
A high-sensitivity context-dependent fear conditioning
protocol (modified from 24) was also tested in separate
cohorts of APPswe/PS1ΔE9 female mice at 5, 8 and 10
months of age. Mice were habituated in the same manner
as described previously. The test chamber was identical,
with the addition of a scent cue (coconut extract 1:500 in
water, McCormick) placed underneath the grid floor. In
the Training Session, mice were placed in the test cham-
ber and allowed to explore for 30 seconds. Mice were
then exposed to the same unconditioned stimulus as in
the previous paradigm (US, 0.6 mA) for two seconds.
Mice remained in the chamber for an additional 35 sec-
onds to measure immediate freezing response. 24 hours
later, mice were placed in the same test chamber for four
minutes without US administration, and time freezing
was measured.
Statistical analysis
Data were analyzed with Univariate Analysis of Variance
(ANOVA) using SPSS Statistics 20 software. For Figure 1,
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http://www.molecularneurodegeneration.com/content/8/1/18analysis was performed on data in 2x2 (treatment x ve-
hicle or treatment x sex) between-subjects factorial de-
sign. For Figures 2, 3 and 4, analysis was performed in a
2x2 (genotype x sex) between-subjects factorial design
for each treatment group, or a 2x2x2 (genotype x sex x
treatment) between-subjects factorial design, and main
effects and interactions were analyzed. Homogeneity of
variance was met for all tests, unless noted otherwise.
Significant p-value was set to 0.05.
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